

## CHRISTOPHER N. TA, M.D.

### PROFESSOR

Byers Eye Institute at Stanford  
Department of Ophthalmology  
2452 Watson Court  
Palo Alto, CA 94303

---

#### PROFESSIONAL POSITIONS

Professor, Stanford University, School of Medicine (2012-present)  
Associate Professor, Stanford University, School of Medicine (2007-2012)  
Assistant Professor, Stanford University, School of Medicine (2000-2006)  
Co-Director of Residency Program, Department of Ophthalmology (2012)  
Director of Residency Program, Department of Ophthalmology (2003-2012)  
Assistant Residency Director, Department of Ophthalmology (1999-2003)  
Acting Assistant Professor, Stanford University, School of Medicine (1999-2000)  
Consultant, Department of Veterans Affairs, Palo Alto Health Care System (2002-2008)

#### EDUCATION

University of Texas, Dallas, Texas, Fellowship in Cornea, External Diseases, and Refractive Surgery (1998-1999)

Stanford University Medical Center, Stanford, California, Residency in Ophthalmology (1995-1998)

Kaiser Permanente Hospital, Oakland, California, Internship in Internal Medicine (1994-1995)

University of Minnesota Medical School, Minneapolis, Minnesota (1990-1994)

University of Minnesota, College of Liberal Arts, Minneapolis, Minnesota (1986-1990)

#### BOARD EXAM CERTIFICATION

Recertified by American Board of Ophthalmology – January 2011 to December 2020

#### PEER-REVIEWED PUBLICATIONS

1. Tan XW, Hartman L, Tan KP, Poh R, Myung D, Zheng LL, Waters D, Noolandi J, Beuerman RW, Frank CW, **Ta CN**, Tan DTH, Mehta JS. "In vivo biocompatibility of two PEG/PAA interpenetratingpolymer networks as corneal inlays following deep stromal pocket implantation." *Journal of Material Science: Materials in medicine*. 2013.

2. Ko MS and **Ta CN**. "Should we be concerned about antibiotic resistance when using intravitreal injections." *Expert Reviews in Ophthalmology*. 2012;7(5):393-395.
3. Charalel RA, Engberg K, Noolandi J, Cochran JR, Frank C, **Ta CN**. "Diffusion of Protein Through the Human Cornea." *Ophthalmic Research*. 2012;48(1):50-55.
4. Nentwich MM, Rajab M, **Ta CN**, He L, Grueterich M, Haritoglou C, Gandorfer A, Kampik A, Miño De Kaspar H. "Application of 10% povidone iodine reduces conjunctival bacterial contamination rate in patients undergoing cataract surgery." *Eur J Ophthalmol*. 2012. July; 22 (4) 541-6.
5. Yu C and **Ta CN**. "Prevention of post cataract endophthalmitis: evidence based medicine." *Current Opinion in Ophthalmology*. 2012 Jan;(1):19-25.
6. Waters D, Engberg K, Parke-Houben R, **Ta CN**, Jackson A, Toney M, Frank C. "Structure and Mechanism of Strength Enhancement in Interpenetrating Polymer Network Hydrogels." *Macromolecules*. 2011; 44(14):5776-5787.
7. Hartmann L, Watanabe K, Zheng LL, Kim C-Y, Beck SE, Huie P, Noolandi J, Cochran JR, **Ta CN**, Frank CW. "Towards the development of an artificial cornea: improved stability of interpenetrating polymer networks." *Journal of Biomedical Materials Research: Part B Applied Biomaterials*. 2011 July; 98B: 8-17.
8. **Ta CN** and Sun Y. "Corneal decompensation in Axenfeld-Rieger syndrome and associated histopathological findings." *Minerva Oftalmologica*. 2011. March; 53(1): 29-30.
9. Sáles CS, Johnston LJ, **Ta CN**. "Long-term clinical course of dry eye in patients with chronic graft-versus-host disease referred for eye examination." *Cornea*. 2011 Feb; 30(2):143-149.
10. Moss JM, Sanislo SR, **Ta CN**. "Antibiotic susceptibility patterns of ocular bacterial flora in patients undergoing intravitreal injections." *Ophthalmology*. 2010 Nov;117(11):2141-5.
11. Waters D, Engberg K, Parke-Houben R, Hartmann L, **Ta CN**, Toney M, Frank C. "Morphology of photopolymerized end-linked poly (ethylene glycol) hydrogels by small angle x-ray scattering." *Journal of Macromolecules*. 2010 July; 43, 6861-6870.
12. He L, **Ta CN**, Miño de Kaspar H. "One-day application of topical moxifloxacin 0.5% to select for fluoroquinolone-resistant coagulase-negative *Staphylococcus*." *J Cataract Refract Surg*. 2009 Oct;35(10):1715-8.
13. Miño De Kaspar H, **Ta CN**, Froehlich SJ, Schaller UC, Engelbert M, Klauss V, Kampik A. "Prospective study of risk factors for conjunctival bacterial contamination in patients undergoing intraocular surgery." *Eur J Ophthalmol*. 2009 Sep-Oct;19(5):717-22.

14. Moss JM, Sanislo SR, **Ta CN**. "A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections." *Ophthalmology*. 2009 Aug;116(8):1498-501.
15. He L, **Ta CN**, Hu N, Sinnar S, Miño de Kaspar H. "Prospective randomized comparison of 1-day and 3-day application of topical 0.5% moxifloxacin in eliminating preoperative conjunctival bacteria." *J Ocul Pharmacol Ther*. 2009 Aug; 25(4):373-8.
16. Yactayo-Miranda Y, **Ta CN**, He L, Kreutzer TC, Nentwich MM, Kampik A, Mino de Kaspar H. "A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis." *Graefes Arch Clin Exp Ophthalmol*. 2009 Jul;24(7):993-8.
17. **Ta CN**, He L, Mino de Kaspar H. "In vitro antibiotic susceptibility of preoperative normal conjunctival bacteria." *Eye*. 2009 Mar; 23(3):559-60.
18. Moss JM, Nguyen D, Liu YI, Singh K, Montague A, Egbert PR, de Kaspar HM, **Ta CN**. "Comparison of one-day vs one-hour application of topical gatifloxacin in eliminating conjunctival bacterial flora." *Ophthalmology*. 2008 Nov; (115):2013-2016.
19. **Ta CN**, Chan I, Dhatt HS, Paterno J, Fisher E, Singh K, Montague A, Egbert P, Cockerham G, de Kaspar HM. "Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application." *Journal of Ocular Pharmacology and Therapeutics*. 2008 Aug; 24(4): 427-31.
20. DeCaro JJ, **Ta CN**, Ho HV, Cabael L, Hu N, Sanislo SR, Blumenkranz MS, Moshfeghi DM, Jack R, de Kaspar HM. "Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections." *Retina*. 2008 Jun; 28(6):877-883.
21. Myung D, Farooqui N, Zheng LL, Koh W, Gupta S, Bakri A, Noolandi J, Cochran JR, Frank CW, **Ta CN**. "Bioactive interpenetrating polymer networks hydrogels that support corneal epithelial wound healing." *Journal of Biomedical Materials Research*. 2008 May; 15. 90A(1):70-81.
22. Myung D, Wiseman M, Waters D, Duhamel P-E, Noolandi J, **Ta C**, Frank CW. "Progress in the development of interpenetrating polymer network hydrogels." *Polymers for Advanced Technologies*." 2008 Apr; 19(6): 647-657.
23. Myung D, Duhamel P-E, Cochran JR, Noolandi J, **Ta CN**, Frank CW. "Development of hydrogel-based keratoprostheses: a materials perspective." *Biotechnol Prog*. 2008 May-Jun; 24(3): 735-741.
24. De Kaspar HM, **Ta CN**, Engelbert M, Mette M, Thiel M, Kampik A. "Effects of intravitreal corticosteroid in the treatment of staphylococcus aureus-induced experimental endophthalmitis." *J Retina & Vitreous Diseases*. 2008 Feb; 28(2):326-332.

25. **Ta CN**, Egbert PR, Singh K, De Kaspar HM. "Prospective comparative evaluation of povidone-iodine (10% for 5 minutes versus 5% for 1 minute) as prophylaxis for ophthalmic surgery." *J. Cataract and Refract Surg.* 2008 Jan; 34(1): 171-172.
26. Myung D, Farooqui N, Waters D, Schaber S, Koh W, Carrasco M, Noolandi N, Frank CW, **Ta CN**. "Glucose-permeable interpenetrating polymer network hydrogels for corneal implant applications: a pilot study." *Current Eye Research.* 2008 Jan;33(1):29-42.
27. Miño De Kaspar H, Kreutzer TC, Aguirre-Romo I, **Ta CN**, Dudichum J, Bayrhof M, Klauss V, Kampik A. "A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora." *Am J Ophthalmol.* 2008 Jan; 145(1): 136-142e2.
28. Myung D, Koh WG, Ko J, Hu Y, Carrasco M, Noolandi J, **Ta CN**, and Frank CW. "Biomimetic strain hardening in interpenetrating polymer network hydrogels." *Polymer.* 2007, 48(18), 5376-5387.
29. **Ta CN**, Lin RC, Singh G, Miño De Kaspar H. "Prospective study demonstrating efficacy of combined preoperative three-day application of antibiotics and povidone-iodine irrigation." *Annals of Ophth.* 2007 Oct; 39(4): 313-317.
30. **Ta CN**, Sinnar S, He L, Myung D, Mino De Kaspar H. "Prospective randomized comparison of 1-day versus 3-day application of topical levofloxacin in eliminating conjunctival flora." *Eur J Ophthalmol.* 2007 Sep-Oct; 17(5):689-95.
31. Farooqui N, Myung D, Koh K, Masek M, Dalal R, Carrasco MR, Noolandi N, Frank CW, **Ta CN**. "Histological processing of pH-sensitive H93ydrogels used in corneal implant applications." *J. Histotechnology.* 2007 Sep; 30(3): 157-163.
32. Sun Y, Jain A, **Ta CN**. "Aspergillus fumigatus keratitis following laser in situ keratomileusis." *J Cataract Refract Surg.* 2007 Oct; 33(10):1806-7.
33. **Ta CN**. "Topical antibiotic prophylaxis in intraocular injections." *Arch Ophthalmol.* 2007 Jul; 125(7):972-4.
34. Myung D, Koh W, Bakri A, Zhang F, Marshall A, Ko J, Noolandi J, Carrasco M, Cochran JR, Frank CW, **Ta CN**. "Design and fabrication of an artificial cornea based on a photolithographically patterned hydrogel construct." *Biomed MicroDevices.* 2007 Dec; 9:911-922.
35. Koss MJ, Eder M, Blumenkranz MS, Klauss V, **Ta CN**, de Kaspar HM. "[The effectiveness of the new fluoroquinolones against the normal bacterial flora of the conjunctiva.]" *Ophthalmologe.* 2007; 104: 21-7.

36. Ou JI, **Ta CN**. "Endophthalmitis prophylaxis." *Ophthalmol Clin North Am.* 2006 Dec; 19(4): 449-56.
37. **Ta CN**, He L, Nguyen E, De Kaspar HM. "Prospective randomized study determining whether a 3-day application of ofloxacin results in the selection of fluoroquinolone-resistant coagulase-negative staphylococcus." *Eur J Ophthalmol.* 2006 May-Jun;16(3):359-64.
38. Myung D, Derr K, Huie P, Noolandi J, Ta KP, **Ta CN**. "Glucose permeability of human, bovine, and porcine corneas in vitro." *Ophthalmic Res.* 2006 Jan; 38(3):158-163.
39. Sonego-Krone S, Sanchez-Di Martino D, Ayala-Lugo R, Torres-Alvariza G, **Ta CN**, Barbosa L, de Kaspar HM. "Clinical results of topical fluconazole for the treatment of filamentous fungal keratitis." *Graefes Arch Clin Exp Ophthalmol.* 2006; 244(7):782-7.
40. Eder M, Fariña N, Sanabria RR, **Ta CN**, Koss M, Samudio M, Cuevas C, Gines A, Simancas M, Klauss V, Miño de Kaspar H. "Normal ocular flora in newborns delivered in two hospital centers in Argentina and Paraguay." *Graefes Arch Clin Exp Ophthalmol.* 2005; 243(11):1098-107.
41. de Kaspar HM, Kreutzer TC, **Ta CN**, Kampik A. "Use of rapid antibiotic susceptibility testing in bacterial endophthalmitis." *Retina.* 2005 Apr-May;25(3):386-7.
42. Miño de Kaspar H, Koss MJ, He L, Blumenkranz MS, **Ta CN**. "Antibiotic susceptibility of preoperative normal conjunctival bacteria." *Am J Ophthalmol.* 2005 April; 139(4): 730-3.
43. Mino de Kaspar H, Chang RT, Singh K, Egbert PR, Blumenkranz MS, **Ta CN**. "Prospective randomized comparison of 2 different methods of 5% povidone-iodine applications for anterior segment intraocular surgery." *Arch Ophthalmol.* 2005 Feb; 123(2):161-5.
44. de Kaspar HM, Kreidl KO, Singh K, **Ta CN**. "Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. *J Glaucoma.* 2004 Dec; 13(6):507-9.
45. **Ta CN**. "Minimizing the risk of endophthalmitis following intravitreous injections." *Retina.* 2004 Oct; 24(5):699-705.
46. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, Grillone LR, Hutcherson S, Liebmann JM, O'Brien TP, Scott IU, Spaide RF, **Ta CN**, Trese MT. "Evolving guidelines for intravitreous injections." *Retina.* 2004 Oct; 24(5 Suppl):S3-19.
47. Mino De Kaspar H, Chang RT, Shriver EM, Singh K, Egbert PR, Blumenkranz MS, **Ta CN**. "Three-day application of topical ofloxacin reduces the contamination rate of

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.